Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects

Meng-Jie Yang,Hong-Rong Xu,Hui Li,Wei-Li Chen,Fei Yuan,Xue-Ning Li

DOI: https://doi.org/10.2147/dddt.s243924

IF: 4.3188

2020-01-01

Drug Design Development and Therapy

Abstract:Purpose: Aprepitant is used to prevent nausea and vomiting associated with moderately and highly emetogenic chemotherapy. In this open-label, 2-period study, the safety, tolerability, and pharmacokinetics (PK) of aprepitant (EMEND (R)) were evaluated in healthy Chinese and Caucasian subjects. Patients and Methods: Twelve Chinese and 12 Caucasian subjects were to receive a 125 mg single-dose of aprepitant during period 1; subsequently, after 15 days washout, only Chinese subjects were to receive the 3-day regimen in period 2. In each period, serial blood samples were collected and analyzed by a validated liquid chromatographic and mass spectrometric method to characterize aprepitant PK across both groups. Results: In both Chinese and Caucasian subjects, there were no serious adverse events. AUC(0-infinity), C-max, T-max, and t(1/2) were largely comparable between the two ethnicities. Comparing the result of period 1 in Chinese and Caucasian subjects, the geometric least-squares mean maximum plasma concentrations (C-max) were 1482 ng/mL and 1435 ng/mL, and the area under the concentration-time curve (AUCC(0-infinity)) 34,035 hr.ng/mL and 34,188 hr.ng/mL. In period 2, the geometric mean AUC(0-24) on Day 1 and Day 3 were 19,446 hr.ng/mL and 27,843 hr.ng/mL, and the geometric mean C-max, on Day 1 and Day 3 were 1423 ng/mL and 1757 ng/mL, respectively. Conclusion: Aprepitant is generally safe and well tolerated in healthy Chinese and Caucasian subjects. Aprepitant PK is comparable between Chinese and Caucasian subjects following single-dose administration. The PK following a clinical 3-day regimen on healthy Chinese subjects has been characterized.